Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Emerging Therapies Will Need to Demonstrate Improvements Over Standard-of-Care to Justify Premium Pricing, According to Findings from Decision Resources Group
BURLINGTON, Mass., May 6, 2014 /PRNewswire/ -- Decision Resources Group finds that overall, infectious disease (ID) specialists and non-ID physicians (critical care and internal medicine specialists) prefer the branded agents Cubist's Cubicin (daptomycin) and Pfizer's Zyvox (linezolid), respectively, when treating methicillin-resistant Staphylococcus aureus (MRSA) infections in the hospital. Nearly half of surveyed ID specialists indicate they prefer Cubicin for treatment of bloodstream infections and/or endocarditis due to MRSA, whereas less than 20 percent of non-ID specialists indicate preference for Cubicin in these indications. However, both physician groups prefer Zyvox for nosocomial pneumonia due to MRSA, likely driven by post-marketing studies demonstrating its clinical superiority over vancomycin. Despite varying drug preferences between the two physician groups, vancomycin remains their most prescribed antibiotic for MRSA infections by both ID specialists and non-ID physicians, driven by physician familiarity, unrestricted formulary access and lower cost.
Other key findings from the U.S. Physician and Payer Forum report entitled MRSA Infections: How Will U.S. Physician and Payer Receptivity to Novel Therapies Influence the Hospital-Treated Infections Market?:
Comments from Decision Resources Group Analyst Maria Ascano, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.